TetraLogic Pharmaceuticals, Inc. announced the appointment of C. Glenn Begley, PhD, F.R.A.C.P., F.R.C.P.A., F.R.C.Path., as senior vice president of research and development. Dr. Begley, who was previously the vice president and global head of hematology and oncology research at Amgen, joins TetraLogic with over 30 years of clinical experience in medical oncology and hematology and in leading the strategy and coordination of oncology research. At the company, Dr. Begley will lead research and development and oversee translational studies to support birinapant, the lead Smac mimetic drug candidate in Phase 2 clinical development.